TTFields and MHC Class I Activators for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as Tumor Treating Fields (TTFields), face challenges in overcoming tumor resistance, particularly due to downregulation of MHC Class I expression, which impairs immune response and reduces the effectiveness of immunotherapy.
Innovation Solution
Concurrent therapy combining TTFields with immune checkpoint inhibitors and compounds that increase MHC Class I expression, either in the same composition or as separate entities, administered simultaneously or sequentially, to enhance immune response and overcome tumor resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TTFields treatment is applied alone, then mitosis disruption and tumor targeting are achieved, but tumor resistance develops due to MHC Class I downregulation
Solution Approach 1:
The patent combines TTFields treatment with immune checkpoint inhibitors and MHC Class I activators into a multimodal therapy regimen. This merging of different treatment mechanisms (physical field therapy, immunotherapy, and molecular activation) prevents tumor resistance by attacking through multiple pathways simultaneously, thereby maintaining reliable treatment effectiveness against evolving tumor defenses.
Solution Approach 2:
The treatment protocol functions as a composite therapeutic approach, integrating three distinct components: TTFields (physical modality), immune checkpoint inhibitors (biological modality), and MHC Class I activators (molecular modality). This composite strategy addresses both the immediate mitotic disruption need and the long-term immune recognition requirement, overcoming the limitation of single-modality treatments.
2Object-affected harmful factors
If MHC Class I expression is downregulated, then tumor immune evasion is achieved, but adaptive immune response is impaired
Solution Approach 1:
The patent applies MHC Class I activators in advance or concurrently with immune checkpoint inhibitors to prevent the downregulation of MHC Class I expression. By maintaining MHC Class I levels before and during immunotherapy, the treatment ensures that tumors cannot evade immune detection, thereby preserving reliable adaptive immune response while still achieving immune evasion prevention.
Solution Approach 2:
MHC Class I activators serve as intermediary agents that bridge the gap between tumor cells and the immune system. These activators ensure proper MHC Class I expression on tumor cells, enabling effective antigen presentation to T cells and facilitating the immune checkpoint inhibitors' ability to enhance immune response, thus maintaining reliable adaptive immunity.
3Reliability
If immune checkpoint inhibitors are used alone, then immune response is enhanced, but tumor resistance to immunotherapy develops
Solution Approach 1:
The patent merges immune checkpoint inhibitors with TTFields and MHC Class I activators to create a synergistic treatment regimen. This combination ensures that while immune response is enhanced through checkpoint inhibition, the simultaneous presence of TTFields (disrupting tumor cell division) and MHC Class I activators (maintaining antigen presentation) prevents tumor cells from developing resistance to any single component.
Solution Approach 2:
The treatment regimen changes multiple parameters simultaneously: physical field parameters (TTFields frequency and intensity), immunological parameters (checkpoint inhibition), and molecular parameters (MHC Class I expression levels). This multi-parameter approach ensures that tumors cannot adapt to a single change, maintaining reliable immune response enhancement while preventing resistance development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy significantly prevents MHC Class I degradation, restores adaptive immunity, and achieves a synergistic effect in reducing cancer cell viability and tumor volume, overcoming resistance to immune checkpoint inhibitors.
Implementation Method 1
Tumor Treating Fields (TTFields) are low intensity (e.g., 1-3 V/cm) alternating electric fields within the intermediate frequency range (such as, but not limited to, 100-500 kHz) that target solid tumors by disrupting mitosis
Data Source
AI summary
Compositions, systems, and methods for reducing viability of cancer cells and treating cancer, as well as preventing an increase of volume of a tumor present in a body of a living subject, are disclosed. The systems and methods involve application of an alternating field concurrently with administration of at least one composition that increases MHC Class I expression in the cancer cells.